Disease or Syndrome – Page 13

AbbVie’s Rinvoq cleared for giant cell arteritis in US

2 months ago talkbio0Tagged Approved, Giant Cell Arteritis, Inhibitor, Janus kinase, Rinvoq, Steroids, United States Food and Drug Administration, upadacitinib

Giant Cell Arteritis, Rinvoq, upadacitinib, Approved, Janus kinase, Inhibitor, United States Food and Drug Administration, Steroids

Abeona’s $3.1M gene therapy wins FDA nod for rare skin disease

2 months ago talkbio0Tagged Abeona, Abeona 's, Approved, Dermatologic disorders, gene therapy, Hallopeau-Siemens Disease, Infrequent, United States Food and Drug Administration, ZEVASKYN

United States Food and Drug Administration, United States Food and Drug Administration, Infrequent, ZEVASKYN, Abeona, gene therapy, Dermatologic disorders, Hallopeau-Siemens Disease, Approved, Abeona ‘s

FDA decision on Stealth’s Barth syndrome drug delayed, again

2 months ago talkbio0Tagged 3-Methylglutaconic aciduria type 2, Decision, Elamipretide, United States Food and Drug Administration

United States Food and Drug Administration, 3-Methylglutaconic aciduria type 2, Decision, Elamipretide

FDA approves Abeonas skin disease cell therapy

2 months ago talkbio0Tagged Abeona, Approved, gene therapy, Hallopeau-Siemens Disease, Treating, United States Food and Drug Administration, Wounds - qualifier, ZEVASKYN

ZEVASKYN, United States Food and Drug Administration, Hallopeau-Siemens Disease, Approved, Wounds – qualifier, gene therapy, Abeona, Treating

Octagon Therapeutics Ceases Operations Due to R&D Challenges and Unresolved Biology Questions

2 months ago talkbio0Tagged Autoimmune Diseases, B cell immunomodulator program, biology (field), Flatulence, Nordisk alliance, OCT50, Programs - Publication Format

Autoimmune disease biotech, B cell immunomodulator program, OCT50 program, Novo Nordisk alliance, Winding down operations, Unresolved biology challenges

Biohaven, after setbacks, sees shares jump with Oberland Capital funding agreement worth up to $600M

2 months ago talkbio0Tagged Approved, Ataxia, Spinocerebellar, Capital, Investments, non-dilutive, Note (document), secured, United States Food and Drug Administration

Biohaven, Oberland Capital, $600 million investment, troriluzole, spinocerebellar ataxia (SCA), non-dilutive funding, FDA approval, senior secured notes

HHS lifts stop work order on Vaxart’s COVID-19 trial, continues funding for the 10,000-participant study

2 months ago talkbio0Tagged BARDA, Covid Vaccine, COVID19 (disease), Lifting, next-generation, oral pill vaccine, Phase 2b Trial, stop work, Vaccines, Vaxart

Vaxart, COVID-19 vaccine, oral pill vaccine, stop work order lifted, BARDA funding, 10, 000-participant study, Phase 2b trial, next-generation COVID vaccine

France pauses chikungunya vaccinations in the elderly after patient death

2 months ago talkbio0Tagged Adverse event, Age, Chikungunya Fever, Disease Outbreaks, Elderly (population group), France, Latex Fixation Tests, older, Reunion Island, Vaccination, Vaccines

Vaccines, Chikungunya Fever, Elderly (population group), Adverse event, France, Latex Fixation Tests, Reunion Island, Disease Outbreaks, Age, older, Vaccination